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Summary and Comment:
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Summary
The authors previously showed that an A/G
splicing site single nucleotide polymorphism in
the OAS1 gene is strongly correlated to the
basal activity of the antiviral oligoadenylate 
synthetase (OAS). Basal activity was highest 
in individuals with the GG genotype and 
lowest in those with the AA genotype.
In the present study, OAS1 GG and GA
genotypes were increased in type 1 diabetic 
individuals compared with their healthy siblings
(p = 0.0023). The strength of association was
similar to that at IDDM2, where the variable
number of tandem repeats (VNTR) class I
(C/C) genotype was increased in diabetic 
compared with healthy siblings (p = 0.0025).
Since OAS enzyme activity reflects an antiviral
response under the control of interferon-α,
the authors concluded that the host genetic
response to viral infection could influence 
susceptibility to type 1 diabetes.
Comment
A number of genes determining susceptibility
(or resistance) to type 1 diabetes have been
identified, most of which encode important 
factors for the development of the autoimmune
response to islet β-cells [1]. The class II major
histocompatibility complex (MHC) genes on
chromosome 6 account for approximately 50%
of the risk and correspond to the machinery
responsible for autoantigen presentation. The
non-MHC VNTR at the INS/IGF2 locus
(IDDM2) represents another important locus
involved in the expression of the major autoanti-
gen related to type 1 diabetes. Until now, there
has been no association between susceptibility
to type 1 diabetes and genetic loci more specifi-
cally linked to the host response to viral infec-
tion. However, children from the general popu-
lation with the susceptible MHC genotype have
a lower than 10% risk of developing type 1 
diabetes, and more than 50% of monozygotic
twins of type 1 diabetic individuals are discor-
dant for the disease. These facts clearly under-
line the influence of the environment in the
pathogenesis of type 1 diabetes, in particular
viral infections such as congenital rubella and
enterovirus infections.
In their elegant study, Field et al. reported
that, compared with their healthy siblings, type
1 diabetic patients have a very significantly
increased frequency of the single nucleotide
polymorphism genotypes associated with high
OAS activity. This result is consistent with that
of a previous paper from the same group show-
ing persistent activation of the antiviral response
in human type 1 diabetes [2]. As discussed by
the authors, it is unclear why such antiviral
enzyme activity would predispose to the disease,
but two explanations are proposed: first, the
increased enzyme activity during viral infection
could directly damage sensitive β-cells through a
death-promoting process following degradation
of cellular RNA by latent RNase activity known
to be stimulated by OAS; second, the less sus-
ceptible AA genotype — associated with the
production of a proapoptotic isoform of OAS —
may induce a rapid apoptosis of virus-infected
islet β-cells, whereas GG and GA individuals
would be less competent or incompetent at
mounting such antiviral protection. Another
point to be discussed is the evidence for another
discordance between human type 1 diabetes and
a classical animal model of the disease, the non-
obese diabetic (NOD) mouse. Indeed, a previ-
ous interesting study evidenced that the devel-
opment of autoimmune diabetes following
coxsackie B4 (CVB4) infection of NOD mice
depends on the β-cell antiviral response to the
CVB4 infection. The anti-CVB4 response,
mounted by the β-cells in response to interfer-
ons, resulted in a reduced permissiveness to
CVB4 infection and an efficient antiviral protec-
tion by natural killer cells [3].
This study demonstrates a strong
linkage between the development of
type 1 diabetes and a host genetic
determinant of the antiviral response
In summary, this study demonstrates for the
first time a strong linkage between the develop-
ment of type 1 diabetes and a host genetic
determinant of the antiviral response. This link-
age has since been confirmed by another inde-
pendent research group [4]. Further work, how-
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ever, remains to be performed in order to deci-
pher the full meaning and explanation underly-
ing this association.
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The DPP and cardiovascular
protection
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Summary
Although no data are yet available on the impact
of diabetes prevention interventions on hard
clinical outcomes, two recent papers have
addressed this question by examining surrogate
cardiovascular risk factors and by modelling.
The first of these papers, from the Diabetes
Prevention Program (DPP) Research Group,
reports on the changes in blood pressure and
lipids over 3 years in each of three study arms
(placebo, metformin and intensive lifestyle). The
levels of risk factors were well matched at base-
line and the most impressive differences after 3
years were in blood pressure. At baseline, 17%
of participants were on antihypertensive therapy.
At 3 years this had risen to 31% and 32% in the
placebo and metformin groups, respectively, but
to only 23% in the lifestyle group. Furthermore,
the blood pressure had fallen by a mean of 3/2
mmHg more in the lifestyle group than in the
other groups. There were no differences between
the groups in total or LDL cholesterol, but
lifestyle intervention led to a reduction in the
numbers of participants with small, dense,
atherogenic LDL particles, and improved
triglycerides by 0.28 mmol/l and HDL by 0.025
mmol/l compared with the other groups. Of 89
cardiovascular disease (CVD) events occurring
in the trial, there was a non-significant excess
among the lifestyle group. Metformin showed
no benefits compared with placebo, except for
an improvement in LDL particle size and a non-
significant reduction in CVD events.
Over a 30-year time frame, the DPP
lifestyle intervention was estimated 
to reduce the likelihood of developing 
a serious diabetes complication 
from 38% to 30%
Eddy et al. used a sophisticated modelling 
program (Archimedes), which, like a flight simu-
lator, undertakes a whole set of calculations on
disease parameters and physiological functions
to estimate outcomes on theoretical populations.
Archimedes’ estimates of outcomes have been
impressively close to actual findings in a number
of clinical trials relevant to diabetes. Over a 30-
year time frame, the DPP lifestyle intervention
was estimated to reduce the chances of adults
who would have been eligible for the DPP of
developing diabetes from 72% to 61%, the like-
lihood of developing a serious diabetes compli-
cation from 38% to 30%, and the likelihood of a
diabetes death from 13.5% to 11.2%. The
cost/quality-adjusted life-year of lifestyle inter-
vention over 30 years was US $143,000 from a








Fig. 1: Changes in hypertension over time by treatment assign-















p = 0.08 p < 0.001
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